Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 2Unknown 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 26Melanoma 25Stomach Neoplasms 9Neoplasms 8Carcinoma, Renal Cell 7Carcinoma, Hepatocellular 6Squamous Cell Carcinoma of Head and Neck 5Neoplasm Metastasis 5Hodgkin Disease 5Breast Neoplasms 5Triple Negative Breast Neoplasms 4Urinary Bladder Neoplasms 3Prostatic Neoplasms 3Pancreatic Neoplasms 3Lung Neoplasms 3Head and Neck Neoplasms 3Esophageal Squamous Cell Carcinoma 3Uveal Melanoma 2Small Cell Lung Carcinoma 2Sarcoma 2Recurrence 2Mesothelioma, Malignant 2Lymphoma, B-Cell 2Leukemia, Myeloid, Acute 2Gastrointestinal Neoplasms 2Esophageal Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Merkel Cell 2Carcinoma 2Brain Neoplasms 2

Interventions

Cytarabine 35Cyclophosphamide 26Etoposide 18Radiotherapy 16Daunorubicin 16Busulfan 15Peripheral Blood Stem Cell Transplantation 14Methotrexate 14Idarubicin 14Mercaptopurine 12Dexamethasone 12Vincristine 11Thioguanine 9Mitoxantrone 9Doxorubicin 8Asparaginase 8Antilymphocyte Serum 8pegaspargase 7fludarabine phosphate 7Prednisolone 7Polymerase Chain Reaction 7Filgrastim 7Cyclosporine 7Prednisone 6Mycophenolic Acid 5Melphalan 5Leucovorin 5Gene Expression Profiling 5Vindesine 4N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Leukemia × Nivolumab × Clear all
NCT03825367 2022-10-12

Nivolumab in Combination With 5-azacytidine in Childhood Relapsed/Refractory AML

Therapeutic Advances in Childhood Leukemia Consortium

Phase 1/2 Unknown
13 enrolled
Other hematologic neoplasm

Leukemia, Recurrence, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡